Cell therapy

#Cancer treatment #Cell therapy

Virtual care to support patients receiving cell therapies 

Virtual oncology care platform Reimagine Care and The Center for Cancer and Blood Disorders have partnered to support patients receiving advanced cell therapies.  The Advanced Therapy Management (ATM) programme provides a model designed to support outpatient post-infusion monitoring and management of CAR-T and other advanced oncology therapies.    The expansion builds on… Read More

#News

#Cell therapy #Europe #Investment

Cellares extends funding for cell therapy manufacturing 

Cellares has raised $327 million for its cell therapy infrastructure project.  Cellares, which says it is the first Integrated Development and Manufacturing Organization (IDMO), extended its Series D funding thanks to an additional $50 million investment from Prime Radiant Partners.  The investment is set to support the next phase of Cellares’ global Smart Factory… Read More

#Business & Investment #News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

eBook: Where next for cell & gene therapy?

Cell and gene therapies (CGT) have been transformative for the treatment several diseases, particularly haematological cancers and genetic conditions like sickle cell disease, with many new indications in the pipeline. This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment,… Read More

#News

DDW CGT eBook
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Where next for cell & gene therapy?

This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment, and the challenges and opportunities of a changing regulatory landscape.

#DDW eBooks #Intelligence

MRI of the brain
#Cell therapy #epilepsy #Mergers and acquisitions #Neurona Therapeutics #Neuroscience #UCB

UCB to acquire epilepsy specialists Neurona Therapeutics

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio.   Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.  UCB will pay $650 million upfront and up… Read More

#Business & Investment #News

CAR-T cell attacking cancer
#CAR-T #Cell therapy #Eli Lilly #Mergers and acquisitions

Lilly buys in vivo CAR-T developer Kelonia Therapeutics

Eli Lilly has reached an agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7 billion.  Kelonia has developed a proprietary in vivo gene placement system (iGPS0) that uses specially engineered lentiviral-based particles designed to enter T-cells inside the body, allowing the… Read More

#Business & Investment #News

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions #Oncology

AstraZeneca buys in vivo cell therapy specialists EsoBiotec

AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion.  The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers.  ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T… Read More

#Business & Investment #News

Gilead offices
#Advanced Therapies #Arcellx #CAR-T #Cell therapy #Gilead Sciences #Mergers and acquisitions

Gilead Sciences to acquire CAR-T company Arcellx

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion.   Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases.  The companies have an existing collaboration to co-develop and co-commercialise Arcellx’s… Read More

#Business & Investment #News #Trending News

Stem cells
#Cell therapy #Kidswell Bio #Regenerative Medicine #Stem cells #Treehill Partners

Partners launch new regenerative medicine company

Kidswell Bio and Treehill Partners have announced the creation of a new US based regenerative medicine company, Kidswell USA.   The companies say Kidswell USA will be formed for the purpose of accelerating the development of Kidswell’s cell therapy pipeline, currently targeting cerebral palsy (CP) as a lead… Read More

#News

#Advanced Therapies #Cell therapy #Clinical trial #Rare diseases

BOOST appoints Schambye as CEO, advances cell therapy treatment  

Biopharmaceutical company BOOST Pharma has appointed Hans Schambye as Chief Executive Officer.   BOOST, a company developing novel, first–in–class off-the-shelf cell therapies for rare, debilitating paediatric skeletal diseases, announced Schambye has transitioned from his role on the Board of Directors with immediate effect into his new role as… Read More

#News

CAR-T cells attacking a cancer cell
#Advanced Therapies #CAR-T #Cell therapy #Lyell Immunopharma #Lymphoma #Oncology #Phase III trial

CAR-Ts go head-to-head in first-of-its-kind clinical trial

Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel).  The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More

#Cancer Research #News #Trending News

#Advanced Therapies #Autoimmune disease #Cell therapy #Eli Lilly #Orna Therapeutics

Lilly to advance cell therapies after Orna acquisition 

Eli Lilly has acquired biotech company Orna Therapeutics to further develop its pipeline of cell therapies in autoimmune diseases.  Orna is advancing a new class of therapeutics utilising engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease.  The company’s lead programme,… Read More

#Business & Investment #News

2026 ideas
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #Gene editing

CGT in 2026: In vivo, greater specificity and next-gen platforms

What does the coming year hold for advanced therapies? Diana Turner asks industry leaders for their predictions for 2026. 2025 was a mixed year for cell and gene therapies (CGT) with some incredible breakthroughs, but also a withdrawal of many companies from their cell therapy programmes. There is optimism for… Read More

#Exclusive Content #Trends & Analysis

T cells
#Advanced Therapies #Atara #Cell and gene therapy #Cell therapy #FDA #Pierre Fabre Laboratories

FDA rejects second application for off-the-shelf T-cell therapy

The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf" allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA).  The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the FDA as adequate… Read More

#News #Regulatory

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News